Tarsus Pharmaceuticals, Inc.
TARS
Hisse Senetlerindeki Sıralama
#4576
Tarsus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm... Tarsus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm dedicated to advancing and commercializing innovative therapies, primarily focusing on ocular conditions. Its leading investigational drug, TP-03, a novel treatment currently in Phase III trials, is being developed to address blepharitis specifically caused by Demodex mite infestations, as well as meibomian gland disease. Beyond this, Tarsus is also progressing TP-04 for rosacea and TP-05, which targets Lyme disease prevention and aims to reduce community-level malaria. A core element of its development strategy involves lotilaner, a compound utilized to tackle a variety of human diseases across diverse therapeutic areas, encompassing eye care, dermatology, and other medical fields. Established in 2016, the company maintains its headquarters in Irvine, California.
Hisse Fiyatı
$71.12
Piyasa Değeri
$3.33B
Değişim (1 gün)
2.33%
Değişim (1 yıl)
-0.10%
Ülke
US
Ticaret Tarsus Pharmaceuticals, Inc. (TARS)
Kategori
Healthcare
Tarsus Pharmaceuticals, Inc. (TARS) için kazanç
Jun 2026 itibarıyla kazanç TTM: $-44.05M
Tarsus Pharmaceuticals, Inc. şirketinin en son finansal raporlarına göre, mevcut kazancı $-44.05M'dir. 2023 yılında şirket $-135.89M kazanç elde etti, bu 2022 yılındaki $-62.10M kazanca göre önceki yıla göre azalma. Bu sayfada gösterilen kazanç, faiz ve vergiler öncesi kazançtır; yani EBIT.
Tarsus Pharmaceuticals, Inc. için kazanç geçmişi 2018 - 2026
Her yılın sonundaki kazanç
| Yıl | Kazanç | Değiştir |
|---|---|---|
| 2026 (TTM) | $-44.05M | -61.88% |
| 2024 | $-115.55M | -14.97% |
| 2023 | $-135.89M | 118.85% |
| 2022 | $-62.10M | 350.88% |
| 2021 | $-13.77M | -48.63% |
| 2020 | $-26.81M | 474.21% |
| 2019 | $-4.67M | 254.25% |
| 2018 | $-1.32M | 0.00% |
Benzer şirketler veya rakipler için kazanç
| Şirket | Kazanç | Kazanç Farkı | Ülke |
|---|---|---|---|
| $5.27B | -12,073.99% |
US
|
|
| $-3.09B | 6,907.47% |
US
|
|
| $-4.02B | 9,016.74% |
AU
|
|
| - | - |
CH
|
|
| $1.95B | -4,527.96% |
NL
|
